Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 1;15(10):e46314.
doi: 10.7759/cureus.46314. eCollection 2023 Oct.

Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review

Affiliations
Review

Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review

Sarath Gopalan et al. Cureus. .

Abstract

Probiotics, both bacterial and yeast, have long been associated with a beneficial health history and human well-being. Among yeasts, Saccharomyces is a genus that is efficacious in rendering better human health, with Saccharomyces boulardii (S. boulardii) CNCM I-745 being classified as a probiotic agent. The present review highlights the unique properties of S. boulardii and its rolein the prevention of antibiotic-associated diarrhea (AAD) and pediatric acute gastroenteritis (PAGE) in comparison to bacterial probiotics. Its unique properties,such as viability over a wide pH range, inability to acquire antibiotic resistance genes, and property to achieve a steady state rapidly, have given S. boulardii an edge over bacterial probiotics. In AAD patients, prophylactic use of S. boulardii has shown a significantly lower risk of AAD (in comparison to controls) and restored the diversity of gut microbiota. Among Indian children with PAGE, S. boulardii CNCM I-745 was found superior to Lactobacillus rhamnosus GG and four strains of Bacillus clausii in shortening the duration of diarrhea and reducing the length of hospital stay. S. boulardii CNCM I-745 being considered a safe probiotic for use in children and adults also finds recommendations in several international guidelines for the management of acute diarrhea. The current review discusses evidence for the proven efficacy and safety of S. boulardii CNCM I-745 as a probiotic for preventing gastrointestinal disorders.

Keywords: antibiotic-associated diarrhoea; cncm i-745; paediatric acute gastroenteritis; probiotic; saccharomyces boulardii.

PubMed Disclaimer

Conflict of interest statement

The authors have declared financial relationships, which are detailed in the next section.

Figures

Figure 1
Figure 1. Advantages of yeasts as probiotics
Adapted from Shruthi et al., 2022 [6] (CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/))
Figure 2
Figure 2. Some beneficial effects of probiotics on human health
Adapted from Celebioglu et al., 2018 [8]. (Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)) GI: Gastrointestinal
Figure 3
Figure 3. Unique properties of S. boulardii CNCM I-745
Image Credits: All authors
Figure 4
Figure 4. Different potential mechanisms of action of Saccharomyces boulardii
Image Credits: All authors On the left various effects of different pathogenic microbes are shown. On the right, seven different protective effects of S. boulardii are mentioned. Within the lumen of the intestine, S. boulardii may degrade toxins of pathogens, interfere with pathogenic adherence, modulate normal microbiota, and preserve normal intestinal physiology. S. boulardii may also indirectly restore normal SCFA balance and increase secretory IgA levels or act as an immune regulator by influencing cytokine levels. LPS: Lipopolysaccharide; Sb: S. boulardii.

References

    1. Microbiota-brain-gut axis and neurodegenerative diseases. Quigley EM. Curr Neurol Neurosci Rep. 2017;17:94. - PubMed
    1. Probiotics in gastrointestinal diseases: all that glitters Is not gold. Compare D, Sgamato C, Nardone OM, Rocco A, Coccoli P, Laurenza C, Nardone G. Dig Dis. 2022;40:123–132. - PubMed
    1. Role of probiotics in human gut microbiome-associated diseases. Kim SK, Guevarra RB, Kim YT, et al. J Microbiol Biotechnol. 2019;29:1335–1340. - PubMed
    1. Probiotics history. Gasbarrini G, Bonvicini F, Gramenzi A. J Clin Gastroenterol. 2016;50:0–9. - PubMed
    1. Probiotic and potentially probiotic yeasts-characteristics and food application. Staniszewski A, Kordowska-Wiater M. Foods. 2021;10:1036. - PMC - PubMed

LinkOut - more resources